REVIEW Atomoxetine HCl is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is classified as a norepinephrine reuptake inhibitor, and is approved for use in children, adolescents, and adults. Its advantage over stimulants for the treatment of ADHD is that it has less abuse potential than stimulants, is not scheduled as a controlled substance and has proven in clinical trials to offer 24 hour coverage of symptoms associated with ADHD in adults and children.
REFERENCES
[1]
Caballero, Joshua; Nahata, Milap C. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clinical Therapeutics. (2003) 25(12): 3065-3083.
[2]
Thomason, Christine; Michelson, David. Atomoxetine: Treatment of attention deficit hyperactivity disorder: Beyond stimulants. Drugs of Today. (2004) 40(5): 465-473.
[3]
Simpson, Dene; Plosker, Greg L. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. (2004) 64(2): 205-222.
[4]
Foster, Bennie Joe; Lavagnino, Edward Ralph 3-Aryloxy-3-phenylpropylamines Eur. Pat. Appl. (1982), EP 52492 A1 19820526.
All products are stocked and shipped from the SF Bay, California, USA via FedEx, UPS or DHL.
All batches backed with full quality assurance.
??
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
Add to Favorites 
Delete from Favorites 
